Telecoms.com Intelligence's Annual Industry Survey Highlights Increasing Importance Of 'Designed-For' B2B BSS Solutions
16.12.2019 12:00:00 EET | Business Wire | Press release
MDS Global Ltd, a leading BSS-as-a-Service provider, in collaboration with Telecoms.com Intelligence, today announced the findings of their 2019 Annual Industry Survey Report. In the report, dedicated and designed-for modern B2B BSS solutions were highlighted as a key requirement by Communication Service Providers (CSPs), with 84% of respondents identifying B2B as the area where enterprise customers will generate the highest revenue growth in 2020 and beyond.
Based on 540 responses to a survey, the report took an overview of the industry landscape over the last 12 months and provided projections for activity from 2020 and beyond. The OSS/BSS section of the survey highlighted that the B2B segments, including large enterprises (30%), small- and medium-sized enterprises (SMEs) (19%), small office/home office (SOHO) (17%), as well as public sector and wholesale partners, need to be served by a specialist B2B BSS platform. This platform should offer a dedicated digital engagement approach supporting personalised order, workflow and service management demands of enterprises, resellers and partners.
According to the survey, 50% of CSPs already have a separate platform to reflect this sector's demand, and 50% of these require a more digital approach to market engagement. 90% of CSPs agreed that the SME segment specifically requires real-time usage and control and the ability to configure, price and order services via online tools. Defined by service level agreements, business customers often demand higher levels of customisation, shorter time to market for new services, and tend to be less tolerant of failures. But at the same time, they are also less sensitive to price, compared with the consumer market.
Flexibility and customisation for both CSPs and enterprise is also especially important in 5G with its strong virtualisation and software-centric characteristics. The B2B sector is forecast to significantly outweigh the B2C sector as a major source of revenue from 5G services and the report reinforced how important 5G technology is in shaping and scheduling future projects. A staggering 97% of CSPs will use SDN/NFV environments to allow integrated services to be personalised, demonstrating that virtualisation will trigger major BSS change.
Gary Bunney, CEO, MDS Global said, "Currently, most BSS running in Communication Service Providers are hardwired to support traditional enterprise services and incorporate many offline business processes that require high-cost specialist resources to deliver constant change."
He continues, "Today’s market demands low-cost service agility. MDS Global is uniquely placed to assist CSPs in automating service engagement whilst enabling the opportunity that 5G and service personalisation brings to enterprises. We provide a dedicated B2B BSS-as-a-Service platform, decreasing the costs associated with operations, automating customer engagement and providing agility to ensure our CSP customers are able to invent, tailor and launch new services without the hindrance of engineering challenges."
MDS Global's B2B-on-Demand enables cost-efficiency and dedicated service delivery. Download the Telecoms.com Insight 2019 Annual Industry Survey here.
About MDS Global
MDS Global, a leading BSS-as-a-Service provider of VNO, B2B and IoT solutions, look after all aspects of monetisation, assurance and customer steering for complex products and services. We offer a digital operating model in a DevOps context, which enhances stakeholder experiences and provides unprecedented business agility.
Headquartered in the UK, MDS Global’s customers include BT Enterprise (UK), eir (Ireland), iD Mobile from Dixons Carphone (UK), TalkTalk (UK), Telefónica (UK), Vodafone (Germany, Greece and NL), Orange (Belgium), KPN (Netherlands) and Telia (Denmark).
For further information: www.mdsglobal.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191216005010/en/
Contact information
Martine Naughton
MDS Global
Email: martine.naughton@mdsglobal.com
Tel: +44 (0) 7909 475815
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom